Previous close | 0.4000 |
Open | 0.4010 |
Bid | 0.3997 x 900 |
Ask | 0.4029 x 1000 |
Day's range | 0.3981 - 0.4029 |
52-week range | 0.3900 - 2.0890 |
Volume | |
Avg. volume | 4,007,333 |
Market cap | 102.596M |
Beta (5Y monthly) | 3.70 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Joining me today are Ocugen's Chairman, CEO, and Co-Founder Dr. Shankar Musunuri, who will provide a business and financial update; and Dr. Arun Upadhyay, our financial scientific officer, head of research development and medical, who is also on the call to answer questions during the Q&A. Yesterday afternoon, we issued a press release detailing business and operational highlights for the second quarter of 2023.
Wall Street has high hopes for certain stocks over the coming 12 months. Two of them are biotech companies that took center stage during earlier days of the pandemic. Both companies raced to bring a coronavirus vaccine to market.
Joining me today are Ocugen's chairman, CEO and co-founder; Dr. Shankar Musunuri, who will provide a business update; and our chief financial officer and chief business officer, Quan Vu, who will provide a financial update. Earlier this morning, we issued a press release detailing business and operational highlights for the first quarter of 2023.